Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms
Diego Cantoni(Medway School of Pharmacy), Nigel Temperton(Medway School of Pharmacy), Cecilia Di Genova(Medway School of Pharmacy), Joseph Hughes(MRC University of Glasgow Centre for Virus Research), Spyros Lytras(The University of Tokyo), Tobia Fantoni(University of Verona), Martin Mayora Neto(Medway School of Pharmacy), Lucia Lopalco(Vita-Salute San Raffaele University), Claudia Pastori(Vita-Salute San Raffaele University), Gabriel Siracusano(Vita-Salute San Raffaele University)
Cited by 14
Related Papers
SARS-CoV-2 evolution during treatment of chronic infection
|Nature|2021|1.1k
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
|Nature Microbiology|2022|724